Evidence map›Paper›PMID 38808204›Full record

ArticleJournal of contemporary brachytherapy2024

Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Trudy C Wu, Alan Lee, Robert Suh, Talia C Oughourlian, Fereidoun Abtin, Mary Ann Hagio, Sang-June Park, Albert J Chang, Drew Moghanaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of contemporary brachytherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Trudy C WuDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Alan LeeDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Robert SuhDepartment of Radiology, University of California, Los Angeles, CA, United States.
Talia C OughourlianDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Fereidoun AbtinDepartment of Radiology, University of California, Los Angeles, CA, United States.
Mary Ann HagioDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Sang-June ParkDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Albert J ChangDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Drew MoghanakiDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative therapies. In this paper, we presented our institution's initial experience with percutaneous high-dose-rate (HDR) brachyablation for a relapsed stage I NSCLC that had been treated with SBRT 4.3 years earlier. Lung tumor measuring approximately 5 cm in maximum tumor dimension at the time of relapse was histopathologically confirmed to be persistent squamous cell carcinoma, and successfully treated with a single fraction of 24 Gy with HDR brachyablation. Treatment was delivered via two percutaneous catheters inserted under CT-guidance, and treated in less than 20 minutes. The patient was discharged home later the same day without the need for a chest tube, and has been monitored with serial surveillance scans every 3 to 6 months without evidence of further lung cancer progression or complications at 2.8 years post-HDR brachyablation procedure and 7.8 years after initial SBRT.

Indexed as

high-dose-rate brachytherapylung cancersalvagestereotactic body radiation therapy

Identifiers

PMID38808204
PMCPMC11129647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.